亚洲一区二区三区看片,日韩欧美九九九久久久,精品国产日韩亚洲一区在线,久久噜噜噜久久熟女精品

掃碼關(guān)注公眾號           掃碼咨詢技術(shù)支持           掃碼咨詢技術(shù)服務(wù)
  
客服熱線:400-901-9800  客服QQ:4009019800  技術(shù)答疑  技術(shù)支持  質(zhì)量反饋  人才招聘  關(guān)于我們  聯(lián)系我們
欧美黄片av在线观看,办公室秘书中文字幕在线
首頁 > 產(chǎn)品中心 > 一抗 > 產(chǎn)品信息
Mouse Anti-human CD45-FITC antibody (bsm-30083M-FITC)  
訂購熱線:400-901-9800
訂購郵箱:sales@www.lalhoau.cn
訂購QQ:  400-901-9800
技術(shù)支持:techsupport@www.lalhoau.cn
說明書: 100T  
100T/1880.00元
大包裝/詢價(jià)

產(chǎn)品編號 bsm-30083M-FITC
英文名稱 Mouse Anti-human CD45-FITC antibody
中文名稱 FITC標(biāo)記人CD45單克隆抗體
別    名 B220; CD 45; CD-45; cd45 antigen; ec3.1.3.48; CD45R; GP180; GP180; GP 180; L CA; LCA; L-CA; Leukocyte common antigen; LY5; Ly-5 glycoprotein; Protein tyrosine phosphatase receptor type C; Protein tyrosine phosphatase receptor type c polypeptide; protein tyrosine phosphatase, receptor type, C; Receptor-type tyrosine-protein phosphatase C; PTPRC; PTPRC_HUMAN; SCID due to PTPRC deficiency; T200; T200 glycoprotein; T200 leukocyte common antigen; Human homolog of severe combined immunodeficiency due to PTPRC deficiency.  FITC anti-human CD45;
研究領(lǐng)域 細(xì)胞生物  免疫學(xué)  神經(jīng)生物學(xué)  信號轉(zhuǎn)導(dǎo)  干細(xì)胞  細(xì)胞表面分子  糖蛋白  細(xì)胞類型標(biāo)志物  自然殺傷細(xì)胞  淋巴細(xì)胞  t-淋巴細(xì)胞  b-淋巴細(xì)胞  
抗體來源 Mouse
克隆類型 Monoclonal
克 隆 號 HI30
交叉反應(yīng)
產(chǎn)品應(yīng)用
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
理論分子量 143kDa
細(xì)胞定位 細(xì)胞膜 
性    狀 Liquid
免 疫 原 Recombinant human CD45 
亞    型 IgG1
純化方法 affinity purified by Protein G
緩 沖 液 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存條件 Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.
注意事項(xiàng) This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
PubMed PubMed
產(chǎn)品介紹 The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. This PTP contains an extracellular domain, a single transmembrane segment and two tandem intracytoplasmic catalytic domains, and thus belongs to receptor type PTP. This gene is specifically expressed in hematopoietic cells. This PTP has been shown to be an essential regulator of T- and B-cell antigen receptor signaling. It functions through either direct interaction with components of the antigen receptor complexes, or by activating various Src family kinases required for the antigen receptor signaling. This PTP also suppresses JAK kinases, and thus functions as a regulator of cytokine receptor signaling. Four alternatively spliced transcripts variants of this gene, which encode distinct isoforms, have been reported. [provided by RefSeq, Jul 2008].

Function:
Protein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN. Dephosphorylates LYN, and thereby modulates LYN activity.

Subunit:
Binds GANAB and PRKCSH. Interacts with SKAP1. Interacts with DPP4; the interaction is enhanced in a interleukin-12-dependent manner in activated lymphocytes. Contains 2 tyrosine-protein phosphatase domains.

Subcellular Location:
Membrane; Single-pass type I membrane protein. Membrane raft. Note=Colocalized with DPP4 in membrane rafts.

Post-translational modifications:
Heavily N- and O-glycosylated.

DISEASE:
Defects in PTPRC are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-positive (T(-)B(+)NK(+) SCID) [MIM:608971]. A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.
Genetic variations in PTPRC are involved in multiple sclerosis susceptibility (MS) [MIM:126200]. MS is a neurodegenerative disorder characterized by the gradual accumulation of focal plaques of demyelination particularly in the periventricular areas of the brain. Peripheral nerves are not affected. Onset usually in third or fourth decade with intermittent progression over an extended period. The cause is still uncertain.

Similarity:
Belongs to the protein-tyrosine phosphatase family. Receptor class 1/6 subfamily.
Contains 2 fibronectin type-III domains.
Contains 2 tyrosine-protein phosphatase domains.

SWISS:
P08575

Gene ID:
5788

Database links:

Entrez Gene: 5788 Human

Omim: 151460 Human

SwissProt: P08575 Human

Unigene: 654514 Human



產(chǎn)品圖片
Flow cytometry staining of normal human peripheral blood cells with CD45/FITC (bsm-30083M-FITC).Total cells were used for analysis.
版權(quán)所有 2004-2026 www.www.lalhoau.cn 北京博奧森生物技術(shù)有限公司
通過國際質(zhì)量管理體系ISO 9001:2015 GB/T 19001-2016    證書編號: 00124Q34771R2M/1100
通過國際醫(yī)療器械-質(zhì)量管理體系ISO 13485:2016 GB/T 42061-2022    證書編號: CQC24QY10047R0M/1100
京ICP備05066980號-1         京公網(wǎng)安備110107000727號
正宁县| 日土县| 郧西县| 隆安县| 莱州市| 宜州市| 青河县| 淮安市| 临沧市| 荃湾区| 揭阳市| 许昌县| 永清县| 黑山县| 汤阴县| 榆树市| 呼图壁县| 丰台区| 延长县| 疏附县| 横山县| 梅州市| 四子王旗| 元阳县| 祁连县| 安多县| 宁安市| 洞口县| 定远县| 门头沟区| 册亨县| 侯马市| 乌什县| 桦川县| 龙游县| 大冶市| 屯门区| 德昌县| 象山县| 桃园市| 资中县|